A Phase 1b, Open-Label Study of Eftozanermin Alfa (ABBV-621) in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

2024-512640-36-00 Protocol M20-258 Human pharmacology (Phase I) - Other Ended

Start 26 May 2021 · End 6 May 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol M20-258

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 6
Countries 1
Sites 1

Multiple Myeloma

Key facts

Sponsor
AbbVie Deutschland GmbH & Co. KG
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
26 May 2021 → 6 May 2025
Decision date (initial)
2024-08-05
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-512640-36-00
EudraCT number
2020-001983-26
ClinicalTrials.gov
NCT04570631

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Multiple Myeloma

VersionLevelCodeTermSystem organ class
21.0 LLT 10028228 Multiple myeloma 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

AbbVie Deutschland GmbH & Co. KG

Sponsor organisation
AbbVie Deutschland GmbH & Co. KG
Address
Knollstrasse
City
Ludwigshafen Am Rhein
Postcode
67061
Country
Germany

Scientific contact point

Organisation
AbbVie Deutschland GmbH & Co. KG
Contact name
Global Clinical Trials Helpdesk

Public contact point

Organisation
AbbVie Deutschland GmbH & Co. KG
Contact name
Global Clinical Trials Helpdesk

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Ended 1 1
Rest of world
United States
5

Investigational sites

Italy

1 site · Ended
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
NA, Via Piero Maroncelli 40, 47014, Meldola

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Italy 2021-05-26 2025-05-05 2021-09-03 2023-06-29

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-06-25 Italy Acceptable
2024-07-31
2024-08-05